این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Biomedical Journal، جلد ۲۳، شماره ۱، صفحات ۲۱-۳۳
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells
چکیده انگلیسی مقاله Background: Targeted co-delivery of siRNA and a chemotherapeutic drug is an attractive approach to cancer drug design and treatment. This study was carried out to design an anti-Mucin 1 aptamer (Apt)-conjugated chitosan nanoparticle (NP) for targeted co-delivery of insulin-like growth factor receptor 1 (IGF-1R) siRNA and docetaxel (DTX) to SKBR3 cells. Methods: Characterization of nano-drugs, cellular uptake of NPs, cell viability, and gene expression studies were evaluated based on metastatic breast cancer cells. Results: The results of this study showed that NPs had spherical and smooth morphology with 110-118 nm in size and had positive zeta potential (12-14 mV). siRNA and DTX were considerably loaded into NPs. The appropriate conjugation of the Apt to the NPs was affirmed by gel electrophoresis. The Apt-conjugated NPs were observed to enhance the cellular uptake of NPs into the SKBR3 cells. Although the combination treatment significantly decreased the cell viability of SKBR3 cells, the augmentative effect was observed when Apt was conjugated to NPs. Furthermore, Apt-conjugated NPs dramatically reduced the genetic expression of IGF-1R, signal transducers and activators of transcription 3 (STAT3), matrix metalloproteinases (MMP9), and vascular growth factor (VEGF). Conclusion: The targeted NPs may augment the targeting of pathways involved in tumorigenesis and metastasis of breast cancer. Therefore, more animal model experiments are needed to further clarify the efficacy and safety of this functionalized nanodrug.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Reza Jafari
Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;


| Naime Majidi Zolbanin
Pharmacology and Toxicology Department, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran


| Jafar Majidi
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


| Fatemeh Atyabi
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran


| Mehdi Yousefi
Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran


| Farhad Jadidi-Niaragh
Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran


| Leili Aghebati-Maleki
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


| Dariush Shanehbandi
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


| Mohammad-Sadegh Soltani Zangbar
Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran


| Houshang Rafatpanah
Immunology Research Center, Division of Inflammation and Inflammatory Diseases, Mashhad University of Medical Sciences, Mashhad, Iran
نشانی اینترنتی http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-740&slc_lang=other&sid=1
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/125/article-125-1041050.pdf
کد مقاله (doi)
زبان مقاله منتشر شده other
موضوعات مقاله منتشر شده Pharmaceutical Biotechnology
نوع مقاله منتشر شده مقاله کامل
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات